Effects of clinically relevant concentrations of glucosamine on equine chondrocytes and synoviocytes in vitro.

This study investigates how glucosamine, a supplement often used in the treatment of joint diseases, impacts the cells responsible for the maintenance and cushioning of joints in horses. The research provides evidence that glucosamine has limited metabolic effects on these cells, but reveals some anti-inflammatory properties when these cells are exposed to a pro-inflammatory molecule.

Research Methods

• The study examined cells derived from the articular cartilage and synovium (a type of tissue that lines the spaces in joints) from the joints of 8 horses aged 1 to 10 years old.
• These cells, known as chondrocytes (cells present in healthy cartilage) and synoviocytes (cells part of the synovial fluid that lubricates joints), were cultured in the lab and treated with various concentrations of glucosamine, ranging from 0.1 to 20 micrograms per milliliter.
• Some cultures were also treated with interleukin-1 (IL-1), a molecule known to promote inflammation, while controls received no glucosamine or IL-1. Cultures exposed only to IL-1 served as positive controls.
• The cultures were observed under these conditions for 48 hours.

Assays Used In The Study

• Cultures were tested for a range of factors such as proteoglycan and MMP-13 production. Proteoglycans are proteins essential for joint function and health, while MMP-13 (Matrix Metalloproteinase 13) is a protein associated with tissue remodeling and degradation.
• The researchers also examined levels of Prostaglandin E2 (PGE2) and cyclooxygenase-2 (two compounds that play roles in the inflammation process), and microsomal PGE2 synthase (an enzyme involved in PGE2 production).

Study Results

• The results indicated that glucosamine does not affect the production of proteoglycans or MMP-13, regardless of whether the cells are in a non-inflammatory or inflammatory state.
• However, at concentrations of 0.1 and 0.5 micrograms per milliliter, glucosamine significantly reduced the production of microsomal PGE2 synthase by chondrocytes in the presence of IL-1.
• Similarly, glucosamine at concentrations of 0.1 and 5 micrograms per milliliter significantly reduced the production of both this enzyme and PGE2 by synoviocytes when IL-1 was present.

Conclusions

• Overall, the study found that glucosamine has only limited effects on the metabolism of chondrocytes and synoviocytes, as measured by the parameters in this study.
• However, glucosamine demonstrated some anti-inflammatory activity on these cells when they were under inflammatory conditions, as indicated by its ability to reduce the production of certain pro-inflammatory molecules.
• Therefore, the study suggests that glucosamine may be beneficial in clinically relevant concentrations for the treatment of inflammatory joint diseases.